Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.
Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.
Coherus Oncology, Inc. (CHRS) entered into a sales agreement with Leerink Partners LLC allowing "at the market" issuances of its common stock with an aggregate offering price of up to $50.0 million. Leerink may act as sales agent or principal under a Form S-3 shelf registration declared effective on December 8, 2025.
Coherus will pay Leerink a commission of up to 3.0% of gross proceeds from each sale, and either party may terminate the agreement on ten days’ notice. Coherus intends to use any net cash proceeds for general corporate purposes, including working capital.
Coherus Oncology, Inc. (CHRS) filed a prospectus supplement establishing an at-the-market equity program to issue and sell up to $50,000,000 of common stock under its existing $150.0 million shelf registration. Sales will be made from time to time through Leerink Partners LLC as sales agent on the Nasdaq Global Market.
Leerink Partners may conduct sales deemed to be an “at the market offering” under Rule 415, earning up to 3.0% of gross proceeds plus up to $100,000 of reimbursed legal expenses. Coherus expects to use any net proceeds for general corporate purposes, including working capital, R&D, commercial activities and capital expenditures, pending investment in short-term investment-grade securities.
The company highlights risks including potential dilution to investors, fluctuating share sale prices under the ATM, and significant indebtedness under a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, which imposes financial and operational covenants and could adversely affect liquidity if breached.
Coherus Oncology, Inc. (CHRS) is formally ending its existing at-the-market equity offering program under a prior sales agreement. Under that agreement, the company could offer and sell common stock with an aggregate offering price of up to $92,500,000, and had previously registered the offer and sale of up to $64,880,054 of common stock under a January 2026 prospectus. On August 17, 2026, Coherus notified the agent that it was terminating the sales agreement because it is entering into a new sales agreement with a different agent. This supplement terminates the continuous offering under the January 2026 prospectus and the related sales agreement.
Coherus Oncology, Inc. announced a special dividend of contingent value rights (CVRs) tied to its remaining biosimilar business. Stockholders of record of Coherus common stock at 5:00 p.m. Eastern Time on September 30, 2026 (the Record Date) will receive one CVR for each share held.
The CVRs will be distributed on October 7, 2026 and will entitle holders to their pro rata share of any net cash proceeds that Coherus actually receives from selling, licensing, or otherwise monetizing specified “Legacy BioSim Assets,” including patents, an existing royalty stream, cell lines and related materials, during the CVR term. The CVR term runs from October 7, 2026 through October 7, 2028; if no qualifying net proceeds are received in that period, the CVRs will expire without payment.
The CVRs are non-transferable except in limited cases, will not be certificated, carry no voting or dividend rights, and will not be listed or traded. Payments, if any, are subject to deductions for taxes and specified expenses and to restrictions in Coherus’ August 12, 2026 Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, L.P.
Coherus Oncology, Inc. entered into a new senior secured term loan facility of $55,000,000 with Innovatus Life Sciences Lending Fund I, LP and other lenders, maturing in August 2031. On August 14, 2026, Coherus drew the full Tranche A amount and used a portion to repay and terminate its prior senior secured term loan, which had been scheduled to mature in May 2029 and carried interest at 8.0% plus three‑month SOFR. Remaining proceeds are designated for working capital and general business requirements.
The new Term Loans bear a floating rate of 4.15% plus the greater of the Prime Rate or 6.75%, with an initial 36‑month interest‑only period, extendable to 48 months upon achieving specified revenue and market capitalization milestones. Coherus also has the option to draw additional tranches of $25,000,000 and $20,000,000 under certain conditions. The loans are secured by liens on substantially all borrower assets, include a minimum unrestricted cash covenant, facility and prepayment fees, and a 4.00% final fee that can increase to 10.00% if the company begins an insolvency proceeding and receives specified debtor‑in‑possession financing.
Coherus Oncology, Inc. reported Q2 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI sales of $13.6 million. Gross margin from continuing operations was 70%.
Research and development expense fell to $21.4 million and selling, general and administrative expense to $21.0 million, reflecting lower headcount and the exit from biosimilars. The company recorded a Q2 2026 net loss from continuing operations of $33.3 million and total net loss of $20.6 million, partly offset by $12.7 million of income from discontinued operations tied to prior biosimilar divestitures.
At June 30, 2026, Coherus held $105.3 million in cash, cash equivalents and marketable securities, with a $37.2 million 2029 term loan and a $14.8 million revenue participation liability outstanding. Management believes existing liquidity funds operations for at least 12 months but indicates additional capital will be needed to complete development and commercialization plans.
Coherus Oncology reported second quarter 2026 net revenue from continuing operations of $14.3 million, up from $10.3 million a year earlier, driven mainly by LOQTORZI, which generated $13.6 million in net revenue, 15% above the prior quarter. Cost of goods sold was $4.2 million, while R&D and SG&A expenses declined versus 2025 as the company reduced headcount and completed its exit from the biosimilar business.
The company recorded a GAAP net loss from continuing operations of $33.3 million, or $0.22 per share, compared with a $44.9 million loss, or $0.39 per share, in 2025; non-GAAP net loss narrowed to $30.1 million. Cash, cash equivalents and marketable securities totaled $105.3 million at June 30, 2026, down from $172.1 million at year-end 2025. Coherus highlighted clinical progress for tagmokitug and casdozokitug and anticipates publicly disclosing data sets with sufficient maturity in early October 2026.
BlackRock, Inc. reports beneficial ownership of Coherus Oncology, Inc. common stock on a passive basis. BlackRock and certain of its business units collectively hold 8,934,952 shares of Coherus Oncology common stock, representing 5.8% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 8,800,165 shares and sole dispositive power over all 8,934,952 shares, with no shared voting or dispositive power. Various underlying clients and funds have rights to dividends and sale proceeds, but no single such person holds more than five percent of Coherus Oncology’s outstanding common shares.
Coherus Oncology, Inc. filed an 8-K reporting a change in its independent auditor. On June 12, 2026, the Audit Committee dismissed Ernst & Young LLP as the company’s independent registered public accounting firm. EY’s audit reports on the 2024 and 2025 financial statements contained no adverse opinions, disclaimers, or qualifications, and the company reports no disagreements or reportable events with EY, other than a previously disclosed material weakness in internal control over certain inventory reconciliations that has since been remediated.
On the same date, the Audit Committee selected PricewaterhouseCoopers LLP to serve as independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures. EY has been asked to provide, and has provided, a letter to the SEC agreeing with the company’s disclosures, which is included as Exhibit 16.1.
Coherus Oncology director Ali J. Satvat received new equity awards. On June 5, 2026, he was granted 30,000 restricted stock units, each convertible into one share of common stock upon vesting. According to the terms, all RSUs vest 100% on the one-year anniversary of June 3, 2026, subject to his continued service.
He also received a stock option for 60,000 shares of common stock at an exercise price of $1.45 per share. This option vests and becomes fully exercisable on June 3, 2027, conditional on his continued service with the company, and expires on June 5, 2036.